



REEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



August 12, 2023

To,
Listing Compliance Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai - 400 001

Scrip Code: 539561 / REMLIFE

Sub: Outcome of the Board Meeting held on 12.08.2023.

Dear Sir,

This is to inform you that the Board of Directors of the Company at their meeting held today, i.e. on August 12, 2023 has inter alia transacted the following business:

1. Approved the unaudited standalone financial results for the quarter ended June 30, 2023.

Pursuant to Clause 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2023 together with the Limited Review Report of the Statutory Auditors thereon.

The meeting of the Board of Directors of the company commenced at 2:00 pm and concluded at 2:30 pm.

We request you to kindly take the same on record.





REEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



Thanking you,

Yours faithfully,
For Remedium Lifecare Limited



Ashvini Dhuri
Company Secretary & Compliance Officer

Encl: As above.

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, NavSudhir CHS Ltd, 113, TilakNagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of RemediumLifecare Limited (formerly known as Roxy Exports Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

**To,
The Board of Directors of RemediumLifecare Limited
(formerly known as Roxy Exports Limited)**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **RemediumLifecare Limited (formerly known as Roxy Exports Limited)** ('the Company') for the quarter ended 30th June, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended, including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, NavSudhir CHS Ltd, 113, TilakNagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TAORI SANDEEP & ASSOCIATES

Chartered Accountants

FRN: 007414C



Atul Jain

Partner

M. No. 048920

UDIN:23048920BGWMCG1188



Place: Mumbai

Date: August 12, 2023

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2023


(₹ in Lakhs)

Particulars	Quarter Ended		Year Ended	
	30th June, 2023	31st March, 2023	30th June, 2022	31st March, 2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	33046.48	7557.96	9932.74	50983.66
II. Other Income	-	0.00	0.00	0.00
III. Total Income (I +II)	33046.48	7557.96	9932.74	50983.66
IV. Expenses				
Cost of Material Consumed	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	31830.30	7187.08	3090.44	41730.44
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	371.33	170.68	6112.72	7655.24
Employee Benefits Expenses	27.93	28.68	14.17	98.33
Finance Costs	0.00	-9.93	0.24	-7.55
Depreciation and amortisation expenses	1.43	1.40	11.16	15.08
Other Expenses	88.65	461.20	54.39	752.53
Total Expenses (IV)	32319.64	7839.11	9283.13	50244.07
V. Profit/(Loss) before exceptional items and tax (III- IV)	726.84	-281.15	649.61	739.60
VI. Exceptional items	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	726.84	-281.15	649.61	739.60
VIII. Tax Expense				
(1) Current tax	202.21	197.74	0.00	197.74
(2) Deferred tax	0.00	-0.75	0.00	-0.75
(3) Previous Year Tax	0.00	0.00	0.00	0.00
Total Tax	202.21	196.99	0.00	196.99
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	524.63	-478.13	649.61	542.61
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	524.63	-478.13	649.61	542.61
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	524.63	-478.13	649.61	542.61
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)				
XVI. Earnings per equity share (for continuing operation):				
(1) Basic	14.57	-13.28	18.04	15.07
(2) Diluted	14.57	-13.28	18.04	15.07
XVII. Earnings per equity share (for discontinued operation):				
(1) Basic	14.57	-13.28	18.04	15.07
(2) Diluted	14.57	-13.28	18.04	15.07
XVIII. Earnings per equity share (for discontinued & continuing operations)				
(1) Basic	14.57	-13.28	18.04	15.07
(2) Diluted	14.57	-13.28	18.04	15.07

Notes:

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on August 12, 2023. The Statutory Auditors have carried out their audit for the above results.
- (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2023. The Results for the quarter ended June 30, 2023, have been reviewed by the statutory auditors.
- (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

For Remedium Lifecare Limited



VILAS LOKHANDE
(Whole Time Director)
DIN : 01228041



Date: 12.08.2023
Place : Mumbai